NAVB: Message Board for Navidea Biopharmaceuticals, Inc. - InvestorVillage

NAVB   /  Message Board

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous 2500 Messages Top of Message List
Go to Msg #  
MSG # SUBJECT TYPE AUTHOR SENTIMENT RECS DATE POSTED
20281 On the CC, Cope said they cold file an IND for a MT Molecule in 12 months GN dwdinvesting 0 8/22/2017 12:26:33 AM
20280 Re: Repeat: Why has NAVB-MT not taken off yet in the financial community? Well perhaps because even the scientific community is still in transition and on a "very steep" re learning curve on macrophage (M1 and M2) role in disease, inflammation, etc! GN dwdinvesting 0 8/22/2017 12:18:18 AM
20279 "Final" Cambridge Healthtech Institute's Inaugural Targeting Tumor Myeloid Cells Conf. Sept 27-28 published.. MG still chairing session-placement of presentation moved GN moneyonomics 0 8/22/2017 12:07:44 AM
20278 Cambridge..Inaugural Targeting Tumor Myeloid Cells Con..Sept 27-28-Tying science together?-1)MG chairing one session-2)MG only speaker presenting on novel targeting of TAMs-3)Siamon Gordon (SAB) and Alberto Mantovani (keynote) joint M1/M2 studies GN moneyonomics 5 8/21/2017 1:17:30 PM
20277 Re: Repeat: Why has NAVB-MT not taken off yet in the financial community? Well perhaps because even the scientific community is still in transition and on a "very steep" re learning curve on macrophage (M1 and M2) role in disease, inflammation, etc! GN StockVestor99 0 8/21/2017 11:16:10 AM
20276 Re: Repeat: Why has NAVB-MT not taken off yet in the financial community? Well perhaps because even the scientific community is still in transition and on a "very steep" re learning curve on macrophage (M1 and M2) role in disease, inflammation, etc! GN bobrmd 3 8/21/2017 10:59:27 AM
20275 Re: Repeat: Why has NAVB-MT not taken off yet in the financial community? Well perhaps because even the scientific community is still in transition and on a "very steep" re learning curve on macrophage (M1 and M2) role in disease, inflammation, etc! GN Bio Guru 1 8/21/2017 9:55:04 AM
20274 Re: Why has NAVB-MT not taken off..perhaps because even the scientific community is still in transition and on a "very steep" learning curve on macrophage.late as 2014 still confusion--Siamon Gordon (SAB member) and Alberto Mantovani (keynote speaker) GN moneyonomics 1 8/21/2017 9:39:12 AM
20273 Repeat: Why has NAVB-MT not taken off yet in the financial community? Well perhaps because even the scientific community is still in transition and on a "very steep" re learning curve on macrophage (M1 and M2) role in disease, inflammation, etc! GN moneyonomics 3 8/20/2017 9:06:13 PM
20272 Re: Cambridge Healthtech Institute's Inaugural Targeting Tumor Myeloid Cells Conference Sept 27-28---"All tying together":::See 2006 M1/M2 study co authored by Siamon Gordon (SAB member) and Alberto Mantovani (keynote speaker) GN moneyonomics 5 8/20/2017 3:37:35 PM
Previous 2500 Messages Top of Message List
Go to Msg #  


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2016 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.

Loading...